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Abstract The anti-leukemic nucleoside analogs 1-L-D-arabino-
furanosylcytosine (araC) and 9-L-D-arabinofuranosylguanine
(araG) are dependent on intracellular phosphorylation for
pharmacological activity. AraC is efficiently phosphorylated by
deoxycytidine kinase (dCK). Although araG is phosphorylated
by dCK in vitro, it is a preferred substrate of mitochondrial
deoxyguanosine kinase. We have used autoradiography to show
that araC was incorporated into nuclear DNA in Molt-4 and
CEM T-lymphoblastoid cells as well as in Chinese hamster ovary
cells. In contrast, araG was predominantly incorporated into
mitochondrial DNA in the investigated cell lines, without
detectable incorporation into nuclear DNA. These data suggest
that the molecular targets of araG and araC may differ.
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1-L-D-Arabinofuranosylcytosine (araC, Cytosar) is com-
monly used in combination chemotherapy of acute myeloid
and lymphoid leukemias. Similar to other nucleoside analogs,
araC is dependent on intracellular phosphorylation for phar-
macological activity. The initial and rate-limiting phosphory-
lation step is catalyzed by deoxycytidine kinase (dCK). AraC-
MP is further phosphorylated by UMP-CMP kinase and nu-
cleoside diphosphate kinases to araC-TP, which is incorpo-
rated into DNA and subsequently induce cell death [1].
AraC’s guanine congenitor, 9-L-D-arabinofuranosylguanine
(araG) is, similarly to araC, cytotoxic to lymphoid cells. How-
ever, araG is selectively cytotoxic towards T-lymphoblasts
compared to B-lymphoblasts whereas araC exhibits equal tox-
icity toward T- and B-cells [2^4]. The selective T-lymphocyte
toxicity of araG suggests that the compound may be useful in
therapy of T-cell malignancies. However, the poor water sol-
ubility and complicated chemical synthesis of araG have long
prevented it from being evaluated in clinical trials. Recently, a
water soluble prodrug of araG, 2-amino-6-methoxypurine
arabinoside (GW506U78), was developed [5], and initial clin-
ical trials showed promising results in treatment of several
lymphoid malignancies of T-cell lineage [6,7]. AraC and
araG are substrates of dCK in vitro, and it is proposed that
both nucleoside analogs are phosphorylated by dCK in vivo
[2,8]. However, araG is a very poor substrate of dCK, exhib-
iting a Km 100-fold higher than the Km of araC [8,9]. In con-
trast, araG is an e⁄cient substrate of deoxyguanosine kinase
(dGK) [9]. A major di¡erence between dCK and dGK is their
subcellular location: dCK is located in the cytosol or nucleus
whereas dGK is located in the mitochondria [10^12]. Accord-
ingly, araC and araG may be phosphorylated in di¡erent
subcellular compartments depending on which nucleoside ki-
nase catalyzes the phosphorylation. There is evidence that the
mitochondrial deoxyribonucleotide pool is separated from the
cytosolic/nuclear pool [13,14]. Thymidine and the pyrimidine
nucleoside analog 5-bromo-2P-deoxyuridine are incorporated
into mitochondrial, but not nuclear, DNA in cells de¢cient in
expression of cytosolic thymidine kinase 1 but with retained
expression of mitochondrial thymidine kinase 2 [14,15]. These
studies suggest that nucleosides and nucleoside analogs
phosphorylated in the mitochondria may become trapped in
this subcellular compartment. Because of the di¡erent subcel-
lular location of dCK and dGK, we decided to study the
incorporation of araC and araG into nuclear and mitochon-
drial DNA. In summary, we showed that araG is predomi-
nantly incorporated into mitochondrial DNA whereas araC
was incorporated into nuclear DNA.
2. Materials and methods
2.1. Cell culture
The dCK-de¢cient Chinese hamster ovary (CHO) cell line was a gift
from Dr. W. Plunkett. Molt-4 and CEM T-lymphoblast cell lines were
gifts from Dr. J. Balzarini. The CHO cells were cultured in McCoy 5 A
modi¢ed medium, the CEM cells and the Molt-4 cells were cultured in
RPMI 1640. All medium was supplemented with 10% fetal calf serum
(Gibco BRL), 100 U/ml penicillin and 0.1 mg/ml streptomycin. The
stably transfected CHO cell line expressing dCK fused to the green
£uorescent protein was generated as described [10].
2.2. Autoradiography
The cells were cultured on poly-L-lysine-coated chamber slides
(Nunc, Inc.) for 24 h. Cells were labeled with 0.25 WM [3H]thymidine
(DuPont), 0.3 WM [3H]araC or 0.7 WM [3H]araG (Moravek Biochem)
for 6^20 h. The slides were rinsed with phosphate-bu¡ered saline,
¢xated 10 min in methanol:acetic acid (3:1), and washed three times
with ice-cold 10% TCA, once with water and once with methanol. The
slides were coated with Hypercoat photoemultion (Amersham) and
exposed 1^3 weeks at 4‡C. The autoradiographs were developed using
D-11 developer (Kodak).
2.3. Cell proliferation assays
The stably transfected cells were plated in 96-well microtiter plates
at a density of W2U103 cells/well. After 24 h, araC (Sigma) or araG
(a gift from Prof. J. Balzarini, Leuven, Belgium) were added at in-
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dicated concentrations. Cell survival was determined by the metrote-
trazolium assay (Cell Proliferation kit I, Boehringer Mannheim) after
4 days of drug exposure.
3. Results
We incubated the T-lymphoblast cell lines CEM and Molt-4
with radiolabeled dThd, araC and araG. The nucleosides in-
corporated into DNA were detected in situ by autoradiogra-
phy (Fig. 1). CEM and Molt-4 cells incubated with [3H]dThd
exhibited, as expected, e⁄cient incorporation of the nucleo-
side analogs into nuclear DNA, as indicated by a dark stain-
ing in the part of the cells corresponding to the nuclear region.
Cells incubated with araC showed similar autoradiography
patterns as the cells incubated with dThd, indicating incorpo-
ration of araC into nuclear DNA. In contrast, cells incubated
with araG showed a dotted autoradiography pattern distrib-
uted throughout the cells indicating incorporation of the nu-
cleoside analog into mitochondrial DNA. In a few cells, a
darker border was observed close to the plasma membrane.
However, by examining a large number of cells incubated with
araG, we were unable to ¢nd cells that showed autoradiog-
raphy patterns similar to those observed for dThd or araC.
These data suggested that araG was predominantly incorpo-
rated into mitochondrial DNA whereas araC was mainly in-
corporated into nuclear DNA of the lymphoblast cell lines.
We have previously transfected a mutant dCK-de¢cient
CHO cell line with a plasmid expressing the cDNA of human
Fig. 1. Autoradiography of CEM and Molt-4 T-lymphoblast cell lines incubated with [3H]dThd, [3H]araC or [3H]araG.
Fig. 2. Autoradiography of dCK-de¢cient (dCK3) and dCK-expressing (dCK) CHO cells incubated with [3H]dThd, [3H]araC and [3H]araG.
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dCK [10]. We used the transfected and untransfected CHO
cells to further study the di¡erential incorporation of araC
and araG into nuclear and mitochondrial DNA. Autoradiog-
raphy of CHO cells incubated with [3H]dThd showed as ex-
pected dThd incorporated into nuclear DNA independently of
dCK expression (Fig. 2). A faint dotted autoradiography pat-
tern was detected in the cytoplasm of the cells incubated with
[3H]dThd, representing dThd phosphorylation by mitochon-
drial thymidine kinase 2, and its subsequent incorporation
into mitochondrial DNA [13,14]. No incorporation of araC
into either nuclear or mitochondrial DNA was detected in the
dCK-de¢cient cells, whereas the cells reconstituted with dCK
expression e⁄ciently incorporated [3H]araC into nuclear
DNA. CHO cells incubated with [3H]araG showed a dotted
irregular autoradiography pattern distributed throughout the
cells, indicating that the nucleoside analog was incorporated
into mitochondrial DNA. We were unable to detect any cells
that incorporated araG into nuclear DNA. The araG auto-
radiography pattern was similar in both untransfected dCK-
de¢cient cells and the cells reconstituted with dCK expression.
The exclusive incorporation of araG into mitochondrial
DNA in CHO cells, independently of dCK expression, sug-
gests that araG is predominantly phosphorylated by mito-
chondrial dGK in these cells. We further determined the
araC and araG sensitivity of the CHO cell lines with and
without dCK expression (Fig. 3). The dCK-de¢cient cells
were resistant to both araC and araG within the tested drug
concentration range. Expression of dCK restored sensitivity to
araC but no increase in araG sensitivity was observed.
4. Discussion
It is generally believed that cytotoxic nucleoside analogs
exert their pharmacological e¡ects by interfering with nuclear
DNA replication and repair. We have in the present study
shown that the anti-leukemic nucleoside analog araG was in-
corporated into mitochondrial DNA without detectable incor-
poration into nuclear DNA in the investigated cancer cell
lines. In contrast, the cytosine analog araC was only incorpo-
rated into nuclear DNA. The di¡erent incorporation of araC
and araG into nuclear and mitochondrial DNA can be ex-
plained by the intramitochondrial phosphorylation of araG
catalyzed by mitochondrial dGK. Once phosphorylated, the
nucleoside analog becomes trapped in the mitochondria and
cannot be exported to the nuclear/cytosolic deoxyribonucleo-
tide pool. This hypothesis is supported by the exclusive mito-
chondrial DNA incorporation of thymidine and 5-bromo-2P-
deoxyuridine phosphorylated by mitochondrial thymidine ki-
nase 2 [14,15]. Another possible explanation would be that
araG is phosphorylated in the cytosolic/nuclear compartment
by dCK, and that the phosphorylated araG subsequently was
imported to the mitochondria. However, if araG-TP should
have been present at high levels in the cytosolic/nuclear dNTP
pool, it should have become incorporated into nuclear DNA
as well. In summary, we believe that predominant incorpora-
tion of araG into mitochondrial DNA is due to the activity of
dGK as the major araG phosphorylating enzyme in vivo.
AraG is selectively cytotoxic towards T-lymphoblasts com-
pared to B-lymphoblasts whereas araC exhibits equal toxicity
towards T- and B-cells [2^4]. The molecular basis of the di¡er-
ent pharmacological pro¢les of araC and araG is not eluci-
dated, but several studies show that T-cells accumulate higher
levels of araG-TP than B-cells, whereas araC-TP levels are
similar in cells of both B- and T-cell lineages [3,4]. These
¢ndings suggest that the metabolism of araG is di¡erent be-
tween T- and B-cells, and that this di¡erence constitutes a
possible explanation for the selective cytotoxicity. The total
level of araG phosphorylating activity in crude cell extracts
does however not di¡er between B- and T-cell lineages [4].
Based on these ¢ndings, it is tempting to speculate that the
di¡erence in araG-TP accumulation between T- and B-cells
might be due to di¡erences in mitochondrial uptake or intra-
mitochondrial metabolism of araG.
The incorporation of araG into mitochondrial DNA sug-
gests that its pharmacological actions may be caused by in-
terference with mitochondrial DNA replication. However, we
cannot exclude that a low level of araG is phosphorylated by
dCK and incorporated into nuclear DNA, although we were
not able to detect it by the autoradiography method used in
the current study. Recently, Rodriguez and Gandhi reported a
predominant incorporation of araG in S-phase CEM cells,
and they showed that the S-phase cells exhibited highest sen-
sitivity to araG-induced apoptosis [16]. These data suggest
that at least part of the cytotoxic e¡ects caused by araG are
due to its incorporation into nuclear DNA during its replica-
tion in the S-phase. These data, however, do not contradict
that araG may have e¡ects on mitochondrial DNA as well.
Overexpression of the mitochondrial dGK enhances the sen-
sitivity of cancer cell lines to cytotoxic nucleoside analogs [12]
and these data show that the intramitochondrial phosphory-
lation of araG can mediate cytotoxic e¡ects. Furthermore, a
mouse model of purine nucleoside phosphorylase de¢ciency
has been shown to lose both dCK and dGK expression [17],
suggesting that the phosphorylation of deoxyguanosine and
its analogs can mediate toxic e¡ects when phosphorylated
either in the cytosolic/nuclear compartment by dCK or
Fig. 3. Sensitivity of dCK-de¢cient (b) and dCK-expressing (a) CHO cells to the nucleoside analogs araC and araG.
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when phosphorylated in the mitochondria by dGK. Several
pyrimidine nucleoside analogs used in anti-viral therapy can
damage mitochondrial DNA, cause mitochondrial dysfunc-
tion, and subsequent cell death [18]. Adverse e¡ects associated
with mitochondrial DNA damage range from neuropathies
and myopathies to severe multi-organ failure. There are so
far few clinical studies on the adverse e¡ects of araG, but
neuropathy is reported as the dose-limiting toxicity [7]. It
will be important to ¢nd out whether this toxicity is due to
mitochondrial dysfunction.
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